Resources

Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a potential first-in-class treatment for osteoarthritis (OA), today presented new data from its 518-patient Phase II trial of LEVI-04 (ClinicalTrials.gov ID: NCT05618782) at the American College of Rheumatology's annual meeting, ACR Convergence 2026, being held from 6 to 11 November in Orlando, Florida.

Coulter Partners, the global expert building leadership teams for Health, Science, and Technology innovation businesses, successfully led a search assignment for MitoRx Therapeutics (“MitoRx”) and is pleased to announce the placement of Neil Anderson, Ph.D., as Chief Business Officer.

Oyster Therapeutics, formerly Kesmalea Therapeutics, has raised $60 million in Series A financing to advance a new generation of targeted protein degraders for neurodegenerative diseases. The financing will support the company’s lead oral, brain-penetrant tau degrader toward clinical development and further advance its proprietary SELFTAC® platform.

Matthew Durdy to retire as CEO of Cell and Gene Therapy Catapult after fifteen years shaping UK advanced therapies

Press release for PETG PharmaTainer product launch

Discovery Park, Kent’s science and innovation hub, has launched the eighth edition of its Discovery Spark accelerator programme, welcoming 10 startups to its campus in Sandwich.

Pioneer Group – the company leading the regeneration of the Grafton Centre – has announced Cambridge-based Envision Health as the winner of its first accelerator programme, aimed at supporting the city’s early-stage tech companies.

As Most Favoured Nation (MFN) drug pricing policies increase uncertainty around future drug revenues, early-stage biotech companies face greater scrutiny from investors and potential partners.

AI-powered analysis of Phase 3 CHARM trial suggests that Brainomix non-contrast CT (NCCT) technology may help identify severe stroke patients more likely to benefit from CIRARA, supporting more precise patient selection and the design of future stroke trials.

One North Quay, a 23-storey science, technology and innovation campus at Canary Wharf, has reached its full height.

This week, imphatec Ltd. has announced the close of an oversubscribed £1.5M seed round led by SynBioVen, with further participation from angel investors. imphatec is a British synthetic biology pharmaceutical company developing the first customisable-dose subcutaneous implant platform to treat chronic conditions.

Medannex Ltd (Edinburgh) today announced the presentation of updated clinical data from Module 1 of the ongoing ATTAINMENT study of MDX-124 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.

Quell Therapeutics announced that QEL-005, its CD19 B-cell activated Phenotype-Locked™ engineered nTreg therapy, has advanced to the second planned dose cohort in the CHILL Phase 1/2 clinical study.

Industry leaders gathered at Discovery Park on 14 October for The Lab of the Future & Green Chemistry Innovation, an event exploring pharmaceutical AI, automation and green chemistry, with speakers urging the industry to unite to share learnings and knowledge.

NRG Therapeutics announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.

Brainomix, announced the publication of new data from the REVISE PPF multicenter observational study demonstrating the potential of quantitative CT.

PIR International recently partnered with CellCentric in appointing Paolo Pucci as Independent Non-Executive Director.

IMU Biosciences has announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data.

Microbiotica announces the first close of a £36 million ($48 million) Series C financing.

Recursion announced a $200 million underwritten offering of common stock with leading healthcare and institutional investors.